Abstract:Aim: To investigate the population pharmacokinetics (PK) and pharmacodynamics (PD) of bivalirudin, a synthetic bivalent direct thrombin inhibitor, in young healthy Chinese subjects. Methods: Thirty-six young healthy volunteers were randomly assigned into 4 groups received bivalirudin 0.5 mg/kg, 0.75 mg/kg, and 1.05 mg/kg intravenous bolus, 0.75 mg/kg intravenous bolus followed by 1.75 mg/kg intravenous infusion per hour for 4 h. Blood samples were collected to measure bivalirudin plasma concentration and activated clotting time (ACT). Population PK-PD analysis was performed using the nonlinear mixed-effects model software NONMEM. The final models were validated with bootstrap and prediction-corrected visual predictive check (pcVPC) approaches. Results: The final PK model was a two-compartment model without covariates. The typical PK population values of clearance (CL), apparent distribution volume of the central-compartment ( V 1 ), inter-compartmental clearance (Q) and apparent distribution volume of the peripheral compartment ( V 2 ) were 0.323 L·h -1 ·kg -1 , 0.086 L/kg, 0.0957 L·h -1 ·kg -1 , and 0.0554 L/kg, respectively. The inter-individual variabilities of these parameters were 14.8%, 24.2%, fixed to 0% and 15.6%, respectively. The final PK-PD model was a sigmoid E max model without the Hill coefficient. In this model, a covariate, red blood cell count (RBC * ), had a significant effect on the EC 50 value. The typical PD population values of maximum effect ( E max ), EC 50 , baseline ACT value ( E 0 ) and the coefficient of RBC * on EC 50 were 318 s, 2.44 mg/L, 134 s and 1.70, respectively. The inter-individual variabilities of E max , EC 50 , and E 0 were 6.80%, 46.4%, and 4.10%, respectively. Conclusion: Population PK-PD models of bivalirudin in healthy young Chinese subjects have been developed, which may provide a reference for future use of bivalirudin in China.

Solid-phase Synthesis of Bivalirudin and Its Method Optimization

Fmoc Solid-phase Synthesis and Purification of Eptifibatide

Use of Lipase Catalytic Resolution in the Preparation of Ethyl (2S,5r)-5-((benzyloxy)amino)piperidine-2-carboxylate, a Key Intermediate of the Β-Lactamase Inhibitor Avibactam

Quantitation of Bivalirudin, a Novel Anticoagulant Peptide, in Human Plasma by LC-MS/MS： Method Development, Validation and Application to Pharmacokinetics

Liquid Phase Synthesis of the Bioactive Tripeptide Bursin

Expression, Purification and Characterization of the Recombinant Hirudin Variant Iii in the Bacillus Subtilis

Chemobiocatalytic Synthesis of a Low-Molecular-Weight Heparin

Simple and Efficient Methods for Isolation and Activity Measurement of the Recombinant Hirudin Variant 3 from Bacillus Subtilis

Studies on the Fermentation Condition Optimization of Fibrinolytic Enzyme Produced by Armiilaria Luteo-virens Sacc

Preparation of Low Molecular Weight Heparin Using an Ultrasound-Assisted Fenton-system

Detection solution for monitoring reaction endpoint of solid-phase synthetic polypeptide and application of detection solution in solid-phase synthetic bivalirudin

Pharmacokinetics, Pharmacodynamics, Tolerability and Safety of Single Doses of Bivalirudin in Healthy Chinese Subjects.

Formal Synthesis of Anticoagulant Drug Fondaparinux Sodium.

Design, Preparation and in Vitro Bioactivity of Mono-PEGylated Recombinant Hirudin

Method for solid phase synthesis liraglutide

Immobilized high-performance heparin lyase III for efficient preparation of low molecular weight heparin

Population Pharmacokinetics and Pharmaco- Dynamics of Bivalirudin in Young Healthy Chinese Volunteers

Studies on the Separation and Purification of Recombinant Hirudin Variant 3 from the Bacillus Subtilis

The Optimization of the Synthesis Process and the Identification of Levobupivacaine Hydrochloride

Design and Synthesis of Neutralizable Fondaparinux.

Solid-Phase Synthesis of Acyl-Plasminogen-Streptokinase Activator Composite(Apsac) and Its Thrombolytic Properties